z-logo
open-access-imgOpen Access
Monitoring target-specific oral anticoagulants
Author(s) -
Barbara A. Konkle
Publication year - 2014
Publication title -
hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.321
H-Index - 91
eISSN - 1520-4391
pISSN - 1520-4383
DOI - 10.1182/asheducation-2014.1.329
Subject(s) - rivaroxaban , medicine , intensive care medicine , computational biology , warfarin , biology , atrial fibrillation
Target-specific oral anticoagulants are approved for use for the prevention of stroke in atrial fibrillation and for the prevention and treatment of venous thrombosis without the need for laboratory monitoring. However, there are clinical settings in which laboratory measurement of anticoagulant effect is needed. These may include patients with life-threatening bleeding or those requiring emergency surgery, in the setting of renal or hepatic failure, or patients with thrombosis on therapy. This chapter reviews the use of laboratory testing to assess the anticoagulant effect of these drugs. In addition, because these drugs can interfere with other laboratory testing, available data on these interactions are presented.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom